Live Breaking News & Updates on Pharmaceuticals Nasdaq

Stay updated with breaking news from Pharmaceuticals nasdaq. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, June 03, 2024 (GLOBE NEWSWIRE) X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases . ....

United States , Head Of Corporate Patient Affairs , Compensation Committee Of The Board Directors , Pharmaceuticals Inc , Company Contact , Pharmaceuticals Nasdaq , Equity Incentive Plan , Nasdaq Listing Rule ,

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03.06.2024 - BOSTON, June 03, 2024 (GLOBE NEWSWIRE) - X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on May 31, 2024, the company issued inducement . ....

United States , Pharmaceuticals Inc , Pharmaceuticals Nasdaq , Compensation Committee Of The Board Directors , Equity Incentive Plan , Nasdaq Listing Rule ,

X4 Pharmaceuticals to Host Virtual Investor Event on June 27, 2024 to Review New Mavorixafor Clinical Data from Ongoing Phase 2 Trial in Chronic Neutropenia

X4 Pharmaceuticals to Host Virtual Investor Event on June 27, 2024 to Review New Mavorixafor Clinical Data from Ongoing Phase 2 Trial in Chronic Neutropenia
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United States , Pharmaceuticals To Host Virtual Investor Event On , Head Of Corporate Patient Affairs , Company Contact , Pharmaceuticals Nasdaq , Exchange Commission , Host Virtual Investor Event , Review New Mavorixafor Clinical Data , Ongoing Phase , Chronic Neutropenia , Private Securities Litigation Reform Act ,

X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility

X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United States , Adam Mostafa , Exchange Commission , Hercules Capital Inc , Head Of Corporate Patient Affairs , Pharmaceuticals Nasdaq , Drug Administration , Company Contact , Capital Infusion , Priority Review Voucher , Existing Loan , Rare Pediatric Disease Priority Review Voucher , Hercules Capital , Chief Financial Officer , Rare Pediatric Disease , Private Securities Litigation Reform Act ,

X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results And Provides Corporate Updates

X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results And Provides Corporate Updates
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

United States , Paula Ragan , American Society Of Hematology , Pharmaceuticals Nasdaq , Development Rd Expenses , Drug Administration , Clinical Immunology Society , European Medicines Agency , Chief Executive Officer , Rare Pediatric Disease Priority Review Voucher , Key Anticipated Upcoming Milestones , American Society , Cash Equivalents , Restricted Cash , Short Term Marketable Securities , Priority Review Voucher , Administrative Expenses ,